Open AccessCoding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist
Author(s) -
Guzman Cristina B.,
Duvvuru Suman,
Akkari Anthony,
Bhatnagar Pallav,
Battioui Chakib,
Foster Wendra,
Zhang Xiaotian Michelle,
Shankar Sudha S.,
Deeg Mark A.,
Chalasani Naga,
Hardy Thomas A.,
Kazda Christof M.,
Pillai Sreekumar G.
Publication year - 2018
Publication title -
hepatology communications
Language(s) - English
Resource type - Journals
ISSN - 2471-254X
DOI - 10.1002/hep4.1171
Subject(s) - steatosis , alanine , alanine aminotransferase , medicine , endocrinology , antagonist , glucagon , glucagon receptor , alanine transaminase , receptor , chemistry , amino acid , biochemistry , insulin
LY2409021 is a glucagon receptor antagonist that was associated with hepatic steatosis and elevated aminotransferases in phase 2 diabetes studies. We investigated the relationship between selected genetic variants and hepatic steatosis and elevated alanine aminotransferases (ALTs) associated with LY2409021. Patients participated in a 6‐week placebo‐controlled trial (I1R‐MC‐GLDI [GLDI], n = 246) and a 52‐week placebo‐ and active comparator‐controlled trial (I1R‐MC‐GLDJ [GLDJ], n = 158). GLDJ had endpoints at 6 months, including measures of hepatic fat fraction (HFF) by magnetic resonance imaging. The five genes tested were patatin‐like phospholipase domain containing 3 ( PNPLA3 ) (rs738409 and rs738491), transmembrane 6 superfamily member 2 ( TM6SF2 ) (rs58542926), peroxisome proliferative activated receptor gamma coactivator 1 alpha ( PPARGC1A ) (rs4361373, rs3774921, rs2970849), adenylate cyclase 3 ( ADCY3 ) ( rs713586), and insulin‐like growth factor 1 ( IGF‐1 ) (rs1520220). In GLDI, PNPLA3 I148M ( P = 0.001) and TM6SF2 E167K ( P = 0.001) were significantly associated with an increase in ALT at 6 weeks for LY2409021 but not for placebo. In GLDJ, PNPLA3 I148M showed the same effect ( P = 0.007) on ALT at 6 months but the placebo or sitagliptin did not. In GLDJ, both PNPLA3 and TM6SF2 risk‐allele carriers showed increases in HFF that were numerically greater but not statistically significant. The carriers of PNPLA3 and/or TM6SF2 risk alleles showed significantly increased ALT (GLDI, +13.28 U/L in carriers versus +4.84 U/L in noncarriers, P = 4 × 10 –5 ; GLDJ, +14.6 U/L in carriers versus +1.7 in noncarriers, P = 0.0018) and HFF (GLDJ, +5.35% in carriers versus 2.38% in noncarriers, P = 0.048). Elevation of transaminase and HFF were also noted in the noncarriers but at a significantly lower degree. Conclusion: The carriers of PNPLA3 and/or TM6SF2 variant alleles are at risk for hepatic steatosis and elevated ALT levels caused by LY2409021, a glucagon receptor antagonist. More studies are needed to investigate if our observations are generalizable to hepatic steatosis caused by other medications. ( Hepatology Communications 2018;2:561‐570)